Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.14

    ▲ −9.00 (−0.98%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Silence Therapeutics

Executive interview – Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines in the increasingly high-profile sector of RNA therapeutics, using the body’s natural mechanism of RNA interference to inhibit the expression of disease. On the back of two recent strategic deals, on 25 March 2020 the company announced a major collaboration with AstraZeneca to develop novel drugs for cardiovascular, renal, metabolic and respiratory diseases. Here to talk through the details of the AstraZeneca deal and equity investment, strategic initiatives and forthcoming milestones for Silence Therapeutics are Dr Rob Quinn, CFO and Dr John Strafford, Head of Business Development.

Silence Therapeutics (SLN) has a portfolio of siRNA drugs in early-stage testing. SLN124 for iron overload is the most advanced and is entering the clinic in Q120. SLN360 is being developed for cardiovascular disease and an IND is planned for H220.

< Previous
Next >

You may also be interested in these:

Metals & Mining

The Metals Company – equity proposition

Investment Companies

Vantage: Rockwood Strategic – UK small-cap value and active engagement
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.